Project: 3D cell culture platform for personalized ovarian cancer therapy selection.
| Acronym | 3D-SELECT (Reference Number: 113479) |
| Duration | 01/10/2019 - 03/10/2022 |
| Project Topic | The consortium will deliver a platform (3D-SELECT) used for the selection of optimal and personalized ovarian cancer therapy. We will exploit cutting-edge 3D cell-culturing technology and artificial intelligence (AI) analytics to directly correlate the ex-vivo drug sensitivity of actual tumour biopsies with clinical outcome. The 3D-SELECT platform will enable high-throughput, automated and accurate screening of available drugs to significantly improve patient survival. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | VitroScan B.V. | Coordinator | Netherlands |
| 2 | AnaPath Services GmbH | Partner | Switzerland |
| 3 | Oncodia AB | Partner | Sweden |
| 4 | Uppsala University | Partner | Sweden |
| 5 | University of Applied Sciences Northwestern Switzerland | Partner | Switzerland |
| 6 | Robovision BVBA | Partner | Belgium |